Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9,456 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance.
Martin LA, Ribas R, Simigdala N, Schuster E, Pancholi S, Tenev T, Gellert P, Buluwela L, Harrod A, Thornhill A, Nikitorowicz-Buniak J, Bhamra A, Turgeon MO, Poulogiannis G, Gao Q, Martins V, Hills M, Garcia-Murillas I, Fribbens C, Patani N, Li Z, Sikora MJ, Turner N, Zwart W, Oesterreich S, Carroll J, Ali S, Dowsett M. Martin LA, et al. Among authors: gao q. Nat Commun. 2017 Nov 30;8(1):1865. doi: 10.1038/s41467-017-01864-y. Nat Commun. 2017. PMID: 29192207 Free PMC article.
AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo.
Ribas R, Pancholi S, Guest SK, Marangoni E, Gao Q, Thuleau A, Simigdala N, Polanska UM, Campbell H, Rani A, Liccardi G, Johnston S, Davies BR, Dowsett M, Martin LA. Ribas R, et al. Among authors: gao q. Mol Cancer Ther. 2015 Sep;14(9):2035-48. doi: 10.1158/1535-7163.MCT-15-0143. Epub 2015 Jun 26. Mol Cancer Ther. 2015. PMID: 26116361
Tumour kinome re-wiring governs resistance to palbociclib in oestrogen receptor positive breast cancers, highlighting new therapeutic modalities.
Pancholi S, Ribas R, Simigdala N, Schuster E, Nikitorowicz-Buniak J, Ressa A, Gao Q, Leal MF, Bhamra A, Thornhill A, Morisset L, Montaudon E, Sourd L, Fitzpatrick M, Altelaar M, Johnston SR, Marangoni E, Dowsett M, Martin LA. Pancholi S, et al. Among authors: gao q. Oncogene. 2020 Jun;39(25):4781-4797. doi: 10.1038/s41388-020-1284-6. Epub 2020 Apr 19. Oncogene. 2020. PMID: 32307447 Free PMC article.
Differences in the transcriptional response to fulvestrant and estrogen deprivation in ER-positive breast cancer.
Patani N, Dunbier AK, Anderson H, Ghazoui Z, Ribas R, Anderson E, Gao Q, A'hern R, Mackay A, Lindemann J, Wellings R, Walker J, Kuter I, Martin LA, Dowsett M. Patani N, et al. Among authors: gao q. Clin Cancer Res. 2014 Aug 1;20(15):3962-73. doi: 10.1158/1078-0432.CCR-13-1378. Epub 2014 Jun 10. Clin Cancer Res. 2014. PMID: 24916694 Free PMC article. Clinical Trial.
Impact of mutational profiles on response of primary oestrogen receptor-positive breast cancers to oestrogen deprivation.
Gellert P, Segal CV, Gao Q, López-Knowles E, Martin LA, Dodson A, Li T, Miller CA, Lu C, Mardis ER, Gillman A, Morden J, Graf M, Sidhu K, Evans A, Shere M, Holcombe C, McIntosh SA, Bundred N, Skene A, Maxwell W, Robertson J, Bliss JM, Smith I, Dowsett M; POETIC Trial Management Group and Trialists. Gellert P, et al. Among authors: gao q. Nat Commun. 2016 Nov 9;7:13294. doi: 10.1038/ncomms13294. Nat Commun. 2016. PMID: 27827358 Free PMC article. Clinical Trial.
9,456 results